Citations

Clear

4847 citation(s) found for "Yu, Eric".

How to do an Altemeier perineal rectosigmoidectomy for full‐thickness rectal prolapse
Sakata, Shinichiro , McKenna, Nicholas P. , Allawi, Ahmed , D’Angelo, Anne-Lise D. , Chua, Heidi K, Dozois, Eric J. , McKenna, Nicholas P

Mayo Clinic

ANZ Journal of Surgery | January 18, 2021 | Volume: 91 | Issue: 5 | Pages: 1019-1020

10.1111/ans.16572 | PMID 33458932 Get It

The feasibility of low iodine dynamic CT angiography with test bolus for evaluation of lower extremity peripheral artery disease
Inoue, Akitoshi , Vrtiska, Terri J., Lee, Yong S. , Vasconcelos, Rogerio N., Weber, Nikkole M. , Halaweish, Ahmed F., Duba, Irene , Williamson, Eric E. , Fletcher, Joel G , Inoue, Akitoshi , Leng, Shuai , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Vascular | January 18, 2021 | Volume: 29 | Issue: 6 | Pages: 927-937

10.1177/1708538120986304 | PMID 33459205 Get It

Objective This study aims to determine if low iodine dynamic computed tomography angiography performed after a fixed delay or test bolus acquisition demonstrates high concordance with clinical computed tomography angiography (using a routine amount of iodinated contrast) to display lower extremity peripheral arterial disease. Methods After informed consent, low iodine dynamic computed tomography angiography examination (using either a fixed delay or test bolus) using 50 ml of iodine contrast media was performed. A subsequent clinical computed tomography angiography using standard iodine dose (115 or 145 ml) served as the reference standard. A vascular radiologist reviewed dynamic and clinical computed tomography angiography images to categorize the lumen into “not opacified”, “<50% stenosis”, “ 50 ̶70% stenosis”, “>70% stenosis”, and “occluded” for seven arterial segments in each lower extremity. Concordance between low iodine dynamic computed tomography angiography and the routine iodine reference standard was calculated. The clinical utility of 4D volume-rendered images was also evaluated. Results Sixty-eight patients (average age 66.1 ± 12.3 years, male; female = 49: 19) were enrolled, with 34 patients each undergoing low iodine dynamic computed tomography angiography using fixed delay and test bolus techniques, respectively. One patient assigned to the test bolus group did not undergo low iodine computed tomography angiography due to unavailable delayed time. The fixed delay was 13 s, with test bolus acquisition resulting in a mean variable delay prior to image acquisition of 19.5 s (range; 8–32 s). Run-off to the ankle was observed using low iodine dynamic computed tomography angiography following fixed delay and test bolus acquisition in 76.4% (26/34) and 100% (33/33) of patients, respectively ( p = 0.005). Considering extremities with run-off to the ankle and without severe artifact, the concordance rate between low iodine dynamic computed tomography angiography and the routine iodine reference standard was 86.8% (310/357) using fixed delay and 97.9% (425/434) using test bolus ( p < 0.001). 4D volume-rendered images using fixed delay and test bolus demonstrated asymmetric flow in 57.7% (15/26) and 58.1% (18/31) ( p = 0.978) of patients, and collateral blood flow in 11.5% (3/26) and 22.6% (7/31) of patients ( p = 0.319), respectively. Conclusion Low iodine dynamic computed tomography angiography with test bolus acquisition has a high concordance with routine peripheral computed tomography angiography performed with standard iodine dose, resulting in improved run-off to the ankle compared to dynamic computed tomography angiography performed after a fixed delay. This method is useful for minimizing iodine dose in patients at risk for contrast-induced nephropathy. 4D volume-rendered computed tomography angiography images provide useful dynamic information.
Long-read targeted sequencing uncovers clinicopathological associations forC9orf72-linked diseases
DeJesus‐Hernandez, Mariely, Aleff, Ross A., Jackson, Jazmyne L. , Finch, NiCole A., Murray, Melissa E. , McLaughlin, Ian , Harting, John, Graff‐Radford, Neill R. , Oskarsson, Björn , Josephs, Keith A. , Petersen, Ronald C. , Fryer, John Denis , Petrucelli, Leonard , Rademakers, Rosa , Wieben, Eric D. , Blitterswijk, Marka van , Baker, Matthew C, Gendron, Tania F. , Oskarsson, Björn , Josephs, Keith A , Dickson, Dennis W , Rademakers, Rosa , van Blitterswijk, Marka , Murray, Melissa E , Baker, Matthew , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W. , Ebbert, Mark

Mayo Clinic

Brain | January 15, 2021 | Volume: 144 | Issue: 4 | Pages: 1082-1088

10.1093/brain/awab006 | PMID 33889947 Get It

AbstractTo examine the length of a hexanucleotide expansion in C9orf72, which represents the most frequent genetic cause of frontotemporal lobar degeneration and motor neuron disease, we employed a targeted amplification-free long-read sequencing technology: No-Amp sequencing. In our cross-sectional study, we assessed cerebellar tissue from 28 well-characterized C9orf72 expansion carriers. We obtained 3507 on-target circular consensus sequencing reads, of which 814 bridged the C9orf72 repeat expansion (23%). Importantly, we observed a significant correlation between expansion sizes obtained using No-Amp sequencing and Southern blotting (P = 5.0 × 10−4). Interestingly, we also detected a significant survival advantage for individuals with smaller expansions (P = 0.004). Additionally, we uncovered that smaller expansions were significantly associated with higher levels of C9orf72 transcripts containing intron 1b (P = 0.003), poly(GP) proteins (P = 1.3 × 10− 5), and poly(GA) proteins (P = 0.005). Thorough examination of the composition of the expansion revealed that its GC content was extremely high (median: 100%) and that it was mainly composed of GGGGCC repeats (median: 96%), suggesting that expanded C9orf72 repeats are quite pure. Taken together, our findings demonstrate that No-Amp sequencing is a powerful tool that enables the discovery of relevant clinicopathological associations, highlighting the important role played by the cerebellar size of the expanded repeat in C9orf72-linked diseases.
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Ansell, Stephen M. , Maris, Michael B., Lesokhin, Alexander M. , Chen, Robert W., Flinn, Ian W. , Sawas, Ahmed , Minden, Mark D. , Villa, Diego , Percival, Mary‐Elizabeth M. , Foran, James M. , Mei, Matthew , Zain, Jasmine , Akilov, Oleg E. , Johnson, Lisa D. , Catalano, Tina, Petrova, Penka S., Uger, Robert A. , Milea, Anca, Roberge, Kathleen, Shou, Yaping, O’Connor, Owen A. , Mei, Matthew , Akilov, Oleg E , Johnson, Lisa D S , Sievers, Eric L , Lesokhin, Alexander M , Flinn, Ian W , Advani, Anjali S. , Horwitz, Steven M. , Savage, Kerry J. , Querfeld, Christiane , Sievers, Eric L.

Mayo Clinic

Clinical Cancer Research | January 15, 2021 | Volume: 27 | Issue: 8 | Pages: 2190-2199

10.1158/1078-0432.ccr-20-3706 | PMID 33451977 Get It

Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapsed/refractory (R/R) hematologic malignancies. Patients and Methods: Patients with R/R lymphoma received escalating weekly intravenous TTI-621 to determine the maximum tolerated dose (MTD). During expansion, patients with various malignancies received weekly single-agent TTI-621 at the MTD; TTI-621 was combined with rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL) or with nivolumab in patients with Hodgkin lymphoma. The primary endpoint was the incidence/severity of adverse events (AEs). Secondary endpoint included overall response rate (ORR). Results: Overall, 164 patients received TTI-621: 18 in escalation and 146 in expansion (rituximab combination, n = 35 and nivolumab combination, n = 4). On the basis of transient grade 4 thrombocytopenia, the MTD was determined as 0.2 mg/kg; 0.1 mg/kg was evaluated in combination cohorts. AEs included infusion-related reactions, thrombocytopenia, chills, and fatigue. Thrombocytopenia (20%, grade ≥3) was reversible between doses and not associated with bleeding. Transient thrombocytopenia that determined the initial MTD may not have been dose limiting. The ORR for all patients was 13%. The ORR was 29% (2/7) for diffuse large B-cell lymphoma (DLBCL) and 25% (8/32) for T-cell NHL (T-NHL) with TTI-621 monotherapy and was 21% (5/24) for DLBCL with TTI-621 plus rituximab. Further dose optimization is ongoing. Conclusions: TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.
Observation Versus Intervention for Low-Grade Intracranial Dural Arteriovenous Fistulas
Buell, Thomas J. , Ding, Dale , Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Kim, Louis J. , Levitt, Michael R. , Abecassis, Isaac Josh, Bulters, Diederik , Durnford, Andrew , Fox, W. Christopher , Polifka, Adam , Gross, Bradley A. , Hayakawa, M. , Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Alaraj, Ali , Kwasnicki, Amanda , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Starke, Robert M., Satomi, Junichiro, Tada, Yoshiteru , Abla, Adib A. , Lai, Rosalind, Zipfel, Gregory J. , Sheehan, Jason P. , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Rao, Mohana Patibandla, Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Samir, Sur, Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav J. , Frerichs, Kai U., Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , Du, Rose , Levitt, Michael R , Fox, W Christopher , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Lanzino, Giuseppe , Kim, Louis J. , Gross, Bradley , Samaniego, Edgar A , Chen, Stephanie , Phelps, Ryan , Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Neurosurgery | January 14, 2021 | Volume: 88 | Issue: 6 | Pages: 1111-1120

10.1093/neuros/nyab024 | PMID 33582776 Get It

Abstract BACKGROUND Low-grade intracranial dural arteriovenous fistulas (dAVF) have a benign natural history in the majority of cases. The benefit from treatment of these lesions is controversial. OBJECTIVE To compare the outcomes of observation versus intervention for low-grade dAVFs. METHODS We retrospectively reviewed dAVF patients from institutions participating in the CONsortium for Dural arteriovenous fistula Outcomes Research (CONDOR). Patients with low-grade (Borden type I) dAVFs were included and categorized into intervention or observation cohorts. The intervention and observation cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was modified Rankin Scale (mRS) at final follow-up. Secondary outcomes were excellent (mRS 0-1) and good (mRS 0-2) outcomes, symptomatic improvement, mortality, and obliteration at final follow-up. RESULTS The intervention and observation cohorts comprised 230 and 125 patients, respectively. We found no differences in primary or secondary outcomes between the 2 unmatched cohorts at last follow-up (mean duration 36 mo), except obliteration rate was higher in the intervention cohort (78.5% vs 24.1%, P < .001). The matched intervention and observation cohorts each comprised 78 patients. We also found no differences in primary or secondary outcomes between the matched cohorts except obliteration was also more likely in the matched intervention cohort ( P < .001). Procedural complication rates in the unmatched and matched intervention cohorts were 15.4% and 19.2%, respectively. CONCLUSION Intervention for low-grade intracranial dAVFs achieves superior obliteration rates compared to conservative management, but it fails to improve neurological or functional outcomes. Our findings do not support the routine treatment of low-grade dAVFs.
Disease Expression and Familial Transmission of Fuchs Endothelial Corneal Dystrophy With and Without CTG18.1 Expansion
Xu, Timothy T. , Afshari, Natalie A. , Aleff, Ross A., Rinkoski, Tommy A. , Maguire, Leo J., Edwards, Albert O., Brown, William L. , Fautsch, Michael P. , Wieben, Eric D. , Baratz, Keith H. , Li, Yi‐Ju , Patel, Sanjay V.

Mayo Clinic

Investigative Opthalmology & Visual Science | January 14, 2021 | Volume: 62 | Issue: 1 | Pages: 17

10.1167/iovs.62.1.17 | PMID 33444430 Get It

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Chen, Alice P. , Moore, Nancy, Zhao, Yingdong , Palmisano, Alida , Coyne, Geraldine O’Sullivan , Rosenberger, Christina L. , Simpson, Mel, Leong, Stephen , Foster, Jared C. , Konaté, Mariam M. , Das, Biswajit , Karlovich, Chris , Lih, Chih-Jian, Simon, Richard , Li, Ming-Chung, Doroshow, James H. , Polley, Eric, O'Sullivan Coyne, Geraldine , Kummar, Shivaani , Rubinstein, Larry , Williams, P. Mickey , Sims, David, Raghav, Kanwal , Meric‐Bernstam, Funda , Waqar, Saiama N , Lih, Chih‐Jian, Polley, Eric C. , Li, Ming‐Chung, Piekarz, Richard

Mayo Clinic

JCO Precision Oncology | January 12, 2021 | Volume: No volume available | Issue: 5 | Pages: 133-144

10.1200/po.20.00372 | PMID 33928209 Get It

PURPOSE This trial assessed the utility of applying tumor DNA sequencing to treatment selection for patients with advanced, refractory cancer and somatic mutations in one of four signaling pathways by comparing the efficacy of four study regimens that were either matched to the patient's aberrant pathway (experimental arm) or not matched to that pathway (control arm). MATERIALS AND METHODS Adult patients with an actionable mutation of interest were randomly assigned 2:1 to receive either (1) a study regimen identified to target the aberrant pathway found in their tumor (veliparib with temozolomide or adavosertib with carboplatin [DNA repair pathway], everolimus [PI3K pathway], or trametinib [RAS/RAF/MEK pathway]), or (2) one of the same four regimens, but chosen from among those not targeting that pathway. RESULTS Among 49 patients treated in the experimental arm, the objective response rate was 2% (95% CI, 0% to 10.9%). One of 20 patients (5%) in the experimental trametinib cohort had a partial response. There were no responses in the other cohorts. Although patients and physicians were blinded to the sequencing and random assignment results, a higher pretreatment dropout rate was observed in the control arm (22%) compared with the experimental arm (6%; P = .038), suggesting that some patients may have had prior tumor mutation profiling performed that led to a lack of participation in the control arm. CONCLUSION Further investigation, better annotation of predictive biomarkers, and the development of more effective agents are necessary to inform treatment decisions in an era of precision cancer medicine. Increasing prevalence of tumor mutation profiling and preference for targeted therapy make it difficult to use a randomized phase II design to evaluate targeted therapy efficacy in an advanced disease setting.
Identification of Possible Risk Variants of Familial Strabismus Using Exome Sequencing Analysis
An, Joon‐Yong , Jung, Jae Ho , Choi, Leejee , Wieben, Eric D.

Mayo Clinic

Genes | January 10, 2021 | Volume: 12 | Issue: 1 | Pages: 75

10.3390/genes12010075 | PMID 33435129 Get It

Purpose: To investigate candidate genes associated with familial strabismus and propose a theory of their interaction in familial strabismus associated with early neurodevelopment. Methods: Eighteen families, including 53 patients diagnosed with strabismus and 34 unaffected family members, were analyzed. All patients with strabismus and available unaffected family members were evaluated using whole exome sequencing. The primary outcome was to identify rare occurring variants among affected individuals and investigate the evidence of their genetic heterogeneity. These results were compared with exome sequencing analysis to build a comprehensive genetic profile of the study families. Results: We observed 60 variants from 58 genes in 53 patients diagnosed with strabismus. We prioritized the most credible risk variants, which showed clear segregation in family members affected by strabismus. As a result, we found risk variants in four genes (FAT3, KCNH2, CELSR1, and TTYH1) in five families, suggesting their role in development of familial strabismus. In other families, there were several rare genetic variants in affected cases, but we did not find clear segregation pattern across family members. Conclusion: Genomic sequencing holds great promise in elucidating the genetic causes of strabismus; further research with larger cohorts or other related approaches are warranted.
Minimally invasive thymectomy for myasthenia gravis favours left-sided approach and low severity class
Wilshire, Candice L. , Blitz, Sandra, Fuller, Carson , Rückert, Jens C., Li, Feng , Cerfolio, Robert J. , Ghanim, Asem F. , Onaitis, Mark W. , Sarkaria, Inderpal S., Wigle, Dennis A. , Reznik, Scott I. , Bograd, Adam J. , Louie, Brian E. , Fuller, Carson C , Joshi, Vijay, Reznik, Scott , Bograd, Adam J , Vallières, Eric , Louie, Brian E , Blitz, Sandra L, Joshi, Vijay V.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | January 10, 2021 | Volume: 60 | Issue: 4 | Pages: 898-905

10.1093/ejcts/ezab014 | PMID 33538299 Get It

Abstract OBJECTIVES Complete thymectomy is a key component of the optimal treatment for myasthenia gravis. Unilateral, minimally invasive approaches are increasingly utilized with debate about the optimal laterality approach. A right-sided approach has a wider field of view, while a left-sided approach accesses potentially more thymic tissue. We aimed to assess the impact of laterality on perioperative and medium-term outcomes, and to identify predictors of a ‘good outcome’ using standard definitions. METHODS We performed a multicentre review of 123 patients who underwent a minimally invasive thymectomy for myasthenia gravis between January 2000 and August 2015, with at least 1-year follow-up. The Myasthenia Gravis Foundation of America standards were followed. A ‘good outcome’ was defined by complete stable remission/pharmacological remission/minimal manifestations 0, and a ‘poor outcome’ by minimal manifestations 1–3. Univariate and multivariable logistic regression analyses were performed to assess factors associated with a ‘good outcome’. RESULTS Ninety-two percent of thymectomies (113/123) were robotic-assisted. The left-sided approach had a shorter median operating time than a right-sided: 143 (interquartile range, IQR 110–196) vs 184 (IQR 133–228) min, P = 0.012. At a median of 44 (IQR 27–75) months, the left-sided approach achieved a ‘good outcome’ (46%, 31/68) more frequently than the right-sided (22%, 12/55); P = 0.011. Multivariable analysis identified a left-sided approach and Myasthenia Gravis Foundation of America class I/II to be associated with a ‘good outcome’. CONCLUSIONS A left-sided thymectomy may be preferred over a right-sided approach in patients with myasthenia gravis given the shorter operating times and potential for superior medium-term symptomatic outcomes. A lower severity class is also associated with a ‘good outcome’.